ライフサイエンスコーパス: blood product

1 failure within hours of the transfusion of a blood product.

2 clotting factor deficiency is infused with a blood product.

3 OLTs, and 79.6% of them did not receive any blood product.

4 te antibodies or bioactive lipids within the blood product.

5 Of these patients, 80.3% did not receive any blood product.

6 well as their detection and elimination from blood products.

7 others, sexual intercourse, and contaminated blood products.

8 e incidence of TRALI from high plasma volume blood products.

9 ght the importance of developing alternative blood products.

10 the prevention of transmission via blood and blood products.

11 of > or = 500 mL of intravenous fluid and/or blood products.

12 as the use of hemostatic agents and special blood products.

13 s>20/FFP>5) or low (RBCs<20/FFP<5) amount of blood products.

14 hrs of the transfusion of plasma-containing blood products.

15 n be performed safely without the use of any blood products.

16 e screening methods to identify WNV-infected blood products.

17 l LDLT in Jehovah's Witness patients without blood products.

18 ous stem-cell support without the use of any blood products.

19 g and thereby complicate the safe release of blood products.

20 ntly requiring limited amounts of transfused blood products.

21 currently do not include much information on blood products.

22 fections result from transfusion of blood or blood products.

23 od but only 7 (7.4%) could separate and bank blood products.

24 ed with the transfusion of plasma-containing blood products.

25 ns, antibiotics, mechanical ventilation, and blood products.

26 antation, gene therapy and the production of blood products.

27 al intensities seen with MR imaging indicate blood products.

28 pro-oxidant compounds in clinically relevant blood products.

29 a logistical necessity to provide sufficient blood products.

30 uma may be exacerbated by the transfusion of blood products.

31 s, in particular transfusion of contaminated blood products.

32 the use of IV fluids, vasoactive agents, or blood products.

33 mendations supporting the restrictive use of blood products.

34 sible spongiform encephalopathies (TSEs) via blood products.

35 ive variability is the use of intraoperative blood products.

36 rved, and no patient required transfusion of blood products.

37 enitor cells, as well as more-differentiated blood products.

38 re and is prevalent among patients receiving blood products.

39 sponsive voxels or voxels containing chronic blood products.

40 loids received significantly more allogeneic blood products.

41 ecting drug use (IDU) and contaminated blood/blood products.

42 pretransplant contributor to charges, while blood products (23%), room and service (21%), organ acqu

43 pe 1 had acquired HCV through transfusion of blood products (50% compared with 25%; P < 0.001).

44 ensitized groups (P>0.4 for all) in usage of blood products (6411 vs. 6339 units) and time to HTX (28

45 V disease (P=0.0001), the number of units of blood products administered during transplantation (P=0.

46 10.7]; P < 0.001); total number of units of blood products administered during transplantation (rela

47 Blood product administration was normalized for the numb

48 inicians are knowledgeable about appropriate blood product administration, as well as the signs, symp

49 mplementation of DCR reduces crystalloid and blood product administration.

50 Exclusion criteria were anticoagulant or blood product administration.

51 sion-acquired viral infections from blood or blood products, adopted diagnostic tests and procedures

52 Bedside filtration of cellular blood products also diminishes the transmission of cytom

53 Transfusion of allogeneic blood products, although potentially life-saving, is ass

54 ignificant difference in the requirement for blood products among patients with and without varices.

55 fference in the number of patients receiving blood products among the treatment groups.

56 rimary outcome of interest was first 24-hour blood product and fluid resuscitation requirements.

57 rious arrhythmias, as well as similar use of blood products and 28-day mortality.

58 t complications following the transfusion of blood products and are associated with significant morbi

59 A light (PUVA) are used to kill pathogens in blood products and as a treatment of aberrant cell proli

60 persistent state and can be transmitted via blood products and be reactivated in seropositive immuno

61 Among them are blood products and blood meal, which are used as high-qu

62 end points included need for transfusion of blood products and chest tube output.

63 h, and initial (24-hour) and total volume of blood products and fluid administered.

64 wn complication following the transfusion of blood products and is commonly referred to as transfusio

65 has declined in developed countries, unsafe blood products and medical practices continue to increas

66 rotocols featuring immediate availability of blood products and multidisciplinary communication reduc

67 incidence, clinical presentation, associated blood products and organisms, and the most feasible and

68 ers that would allow the detection of bovine blood products and processed animal proteins using tande

69 resting" T cells, which can be isolated from blood products and succumb to cART once activated.

70 The blood products and their interaction responsible for SEC

71 tates have included transfusion of blood and blood products and transplantation of solid organs from

72 1) of patients with a history of exposure to blood products, and 4% (1 of 25) of patients without par

73 equipment, monitors, medicines, oxygen, and blood products, and an absence of meaningful data to gui

74 infected donors and recipients of blood and blood products, and assessment of TTV's aetiological rol

75 ignificant decline in blood loss, the use of blood products, and hospital stay.

76 h's Witnesses regarding the use of blood and blood products, and how to ensure that those patients pr

77 s, readmission and reoperation rates, use of blood products, and lengths of stay in the intensive car

78 LOS pretransplant, blood products, and operating room services represent po

79 mitigate the risks from TSE-infected blood, blood products, and other materials exposed to TSE infec

80 hil antigen antibodies present in transfused blood products, and predisposing factors such as inflamm

81 agement include hemodialysis, transfusion of blood products, and prohemostatic drugs.

82 ze patients' coagulation, reduce exposure to blood products, and to improve patient outcomes.

83 gnosis before live vaccines or nonirradiated blood products are given and before development of infec

84 Although anaphylactic reactions to blood products are rare, the incidence of allergic react

85 Leukoreduced blood products are reportedly comparable to cytomegalovi

86 Babesia spp. and the movement of donors and blood products around the United States has resulted in

87 nd mortality requires rapid delivery of safe blood products as an integral element of advanced trauma

88 optimal care and ensuring judicious usage of blood products, as is keeping abreast of novel therapeut

89 ents exposed to non-virus-inactivated pooled blood products associated with transmission of HCV.

90 Changing blood product availability and composition will lead to

91 Coagulopathy was corrected with appropriate blood products before biopsy.

92 eople with haemophilia who were treated with blood products before the introduction of virus-inactiva

93 rounding the risk of transmission of vCJD by blood products, blood transfusion services in a number o

94 safer to handle and easier to store than wet blood products, but factors such as intraspot variabilit

95 lion typed volunteer donors and 645,646 cord blood products by 2012.

96 ve patients who had received HTLV-I-infected blood products by transfusion.

97 an immunodeficiency virus (HIV) in blood and blood products can be achieved by a sensitive nucleic ac

98 All blood products can cause TRALI, and no specific treatmen

99 However, aged blood products can cause transfusion-related acute lung

100 They were treated between 1969 and 1985 with blood products carrying a high risk of HCV infection, an

101 e unit admission, intubation, transfusion of blood products, central venous catheter placement, prese

102 The United States has thousands of licensed blood product collection centers that produce millions o

103 rategy leads to a significantly lower use of blood products compared to SOC (transfusion guided by IN

104 Lyophilized and recombinant blood product components may have advantages over tradit

105 hreat than the combined risks of receiving a blood product contaminated with HIV-1 or 2, hepatitis C

106 r adjustment for age, gender, comorbidities, blood products, crystalloid/12 hrs, presence of any head

107 Disaster logs, patient injuries, and blood product data were prospectively collected during t

108 The use of blood products did not differ between groups (UFH=2.7+/-

109 atelets were given along with numerous other blood products during posterior spine surgery.

110 Severely malnourished patients require more blood products during surgery and have prolonged postope

111 received transfusions of at least 3 units of blood products during the first 24 hours after admission

112 sfusion of CMV-seronegative and leukoreduced blood products effectively prevents transmission of CMV

113 xclusion criteria were pregnancy, receipt of blood products (except albumin) in the previous 3 months

114 measurements to predict total perioperative blood product exposure and operative mortality.

115 Each 10-unit increase in total perioperative blood product exposure increased the odds of operative d

116 y and those whose HIV infections derive from blood product exposure suggest the presence of a sexuall

117 the UMHS cohort, median total perioperative blood product exposure was 74 units (25th and 75th perce

118 3.8 units (beta+/-SE) of total perioperative blood product exposure.

119 blood donors and patients with FHF, and from blood products (factor VIII and IX clotting-factor conce

120 es, sedative exposures, routes of nutrition, blood products, fluid balance, and modes of ventilatory

121 yed an important role in identifying matched blood products for transfusion.

122 diagnosed and underreported in recipients of blood products from a donor whose blood products may hav

123 dose that inactivates >5 log10 of T cells in blood products, had minimal effect on cytokine synthesis

124 tion on donors and recipients of >20 million blood products handled by the Danish and Swedish blood b

125 ion of lipids accumulated in stored cellular blood products has been made in those cases.

126 ed on donor leukocytes during transfusion of blood products has been shown to impact the recipient's

127 , but the risk for the intraoperative use of blood products has increased.

128 Ehrlichiosis acquired from transfusion of blood products has not been documented in the literature

129 to transfusion of vCJD-contaminated blood or blood products have been described.

130 ve lipids that accumulate in older, cellular blood products, have been replicated in animal models.

131 coagulopathy by proactive resuscitation with blood products in a balanced ratio of RBC:plasma:platele

132 ponents may have advantages over traditional blood products in certain clinical circumstances.

133 efore, maintaining a dependable inventory of blood products in combat support hospitals is essential.

134 ntly been recognized that the transfusion of blood products in critically ill or injured patients inc

135 ssion of variant Creutzfeld-Jakob disease by blood products in humans.

136 veloped management guidelines for the use of blood products in sepsis that would be of practical use

137 reduce bleeding and minimize transfusion of blood products in the setting of clotting factor deficie

138 The utilization of blood products in the treatment of major burn injury sho

139 high rates of transmission through infected blood products, including in medical settings; limited a

140 e risk increases as the number of transfused blood products increase.

141 n the rates of transfusion of RBCs and other blood products, independent of case mix, among patients

142 lop sepsis if they are given high amounts of blood products, indicating an immunocompromised state fo

143 tay > or =15 days, blood usage > or =36 U of blood products, infection, rejection, and global resourc

144 e evidence that the presence of subarachnoid blood products is associated with DNA fragmentation and

145 true incidence of this pulmonary reaction to blood products is currently conjectural at best.

146 iral transmission from contaminated blood or blood products is extremely rare, and in developing coun

147 rare, the incidence of allergic reactions to blood products is similar to the allergic reaction incid

148 it remains controversial whether infusion of blood products is superior to crystalloids alone.

149 Because bacterial contamination of blood products is the most frequent cause of transfusion

150 associated with the administration of equine blood products; its etiologic agent has remained unknown

151 Other outcomes included transfusion of other blood products, major bleeding, and major complications.

152 than the level of infectivity present in the blood product make a significant contribution to underst

153 Discuss the pros and cons of using donor and blood product-management strategies to prevent transfusi

154 tients developing sepsis from a contaminated blood product may meet the clinical definition of transf

155 The infectivity of HGV in blood products may be lower than that of HCV, or the vir

156 Transfusion of "older" blood products may contribute to a higher risk of postop

157 Transfusion of "older" blood products may contribute to a higher risk of postop

158 speculate that cytokine-mobilized peripheral blood products may eventually replace marrow as a source

159 ipients of blood products from a donor whose blood products may have caused TRALI in several transfus

160 ia who received influenza-convalescent human blood products may have experienced a clinically importa

161 dition to more strict criteria of the use of blood products, may improve outcome after TAVI.

162 e residual level of cytomegalovirus (CMV) in blood products measured by quantitative polymerase chain

163 acquired HIV through transfusion of blood or blood products (median age at cancer diagnosis, 13.4 yea

164 Only intraoperative use of blood products, not operative case length, hypotension,

165 and obviates the necessity of using limited blood products obtained from a small number of HPS survi

166 njecting his former girlfriend with blood or blood-products obtained from an HIV type 1 (HIV-1)-infec

167 dicted body weight, p <.001), transfusion of blood products (odds ratio, 3.0; p < 0.001), acidemia (p

168 1.16-58, p = 0.04); maternal transfusion of blood products, odds ratio 7.24 (95% confidence interval

169 involving the thoracic aorta; transfusion of blood products of > or =10 units; and cardiopulmonary by

170 gastrointestinal hemorrhage who refused all blood products on religious grounds.

171 er may limit the toxic effects of persistent blood products on surrounding tissue and may be importan

172 ed to plan for high use of advanced imaging, blood products, operating room availability, nursing res

173 received transplants before HCV screening of blood products or donors, 10.2% developed de novo HCV di

174 approaches, such as the use of concentrated blood products or osteoprogenitor cells in conjunction w

175 n donor, and remove any potentially infected blood products or tissues.

176 ported travel to other countries, receipt of blood products, or drug injection.

177 posing risk to others via blood transfusion, blood products, organ or tissue grafts, and contaminated

178 rative bleeding as evidenced by the units of blood products (packed red blood cells or platelets) tra

179 cardiopulmonary bypass time, transfusion of blood products, postoperative arterial blood gases, and

180 ith and without cold agglutinins in usage of blood products, postoperative day 2 aminotransferase lev

181 The following blood products produced faint VD values: washed red bloo

182 Earlier transfusion with higher blood product ratios (plasma, platelets, and red blood c

183 Blood product ratios of 1:1:1 (338 patients) vs 1:1:2 (3

184 cumentation and four required transfusion of blood products (RBCs, n = 2; platelet, n = 2).

185 Women progressing to 8 U blood products (red blood cells [RBCs] + fresh frozen pl

186 years (P=0.0352), and the number of units of blood products (red blood cells, platelets, or fresh fro

187 transfusion of influenza-convalescent human blood products reduced mortality in patients with influe

188 bumin), bilirubin levels, and intraoperative blood product requirements could be statistically linked

189 tibodies, as well as alternate substances in blood products, result in neutrophil activation, which,

190 actions and limit availability of compatible blood products, resulting in anemia-associated morbidity

191 Chronic blood product shortages, as well as the known and unknow

192 If massive transfusion is anticipated, blood products should be administered from the outset to

193 The risk and benefits of all blood products should be assessed before transfusion.

194 risks of transfusion-related adverse events, blood products should be used judiciously.

195 Transfusion of blood products should not be withheld from surgical pati

196 es, as well as the known and unknown risk of blood products, should serve as the driving force for de

197 Virus inactivation of blood products substantially reduced or eliminated conta

198 Leukocyte reduction of donated blood products substantially reduces the risk of a numbe

199 rs, and the extent to which TTV contaminates blood products such as factor VIII and IX clotting facto

200 Maintaining a robust blood product supply is an essential requirement to guar

201 ow-up, all 6 surviving patients were free of blood product support and thrombopoietic agonists.

202 confirmation of the diagnosis and aggressive blood product support are critical to reduce early morta

203 tients randomly assigned to CC required more blood product support.

204 o perform autologous transplantation without blood-product support.

205 The total number of units of blood products that were transfused during hospitalizati

206 roportionately large quantities of blood and blood products, the immunomodulatory effects of blood tr

207 f HGV contamination of non-virus-inactivated blood products, their use was not associated with high r

208 ation, particularly in terms of the ratio of blood products to each other and the timing of these pro

209 erstand the composition of the available new blood products to use them correctly.

210 Platelets are a frequently requested blood product today and are often in limited supply beca

211 ce interval 1.4 to 15.8; p = .01), number of blood products transfused (odds ratio 1.09; 95% confiden

212 hospital-acquired aspiration, and volume of blood products transfused and fluids administered.

213 which helps to reduce the number of units of blood products transfused in the actively bleeding patie

214 ator-free days, renal failure-free days, and blood products transfused) and compliance with each guid

215 V infection was not related to the number of blood products transfused, a particular surgeon, or a sp

216 4%; P=0.96) or requirement for postoperative blood product transfusion (adjusted OR, 1.17; 95% CI, 0.

217 tality (odds ratio, 0.40; P=0.017), need for blood product transfusion (odds ratio, 0.74; P=0.009), m

218 s is likely related to the administration of blood product transfusion after the onset of fulminant h

219 ndrome continues to be supportive care, with blood product transfusion and antibiotics for infectious

220 nal shock, maternal requirement of allogenic blood product transfusion and lower gestational age were

221 et count), and its use may avoid unnecessary blood product transfusion in patients with cirrhosis and

222 Timely LDLT can be done successfully without blood product transfusion in selected patients.

223 Red blood cell and blood product transfusion in the fetus, neonate, and pre

224 Prehospital blood product transfusion in trauma care remains controv

225 Restrictive blood product transfusion practices following congenital

226 military combat causalities in Afghanistan, blood product transfusion prehospital or within minutes

227 n the incidence of hemostatic reexploration, blood product transfusion rates, morbidity, and mortalit

228 ntly, Jehovah's Witness patients, who refuse blood product transfusion, are usually excluded from liv

229 risk of reoperation for bleeding or need for blood product transfusion.

230 tients (69%), and 28 patients (67%) required blood product transfusion.

231 and related physician orders, demographics, blood products transfusion, and outcomes were collected

232 ump CABG, significantly reduced the rates of blood-product transfusion (50.7% vs. 63.3%; relative ris

233 Early postoperative chest-tube output, blood-product transfusion requirements, and levels of se

234 Pugh B: 26; C: 58) without overt bleeding or blood-product transfusion were prospectively evaluated w

235 2% vs. 2.4%, p = 0.002), had higher rates of blood product transfusions (13.1% vs. 3.1%, p < 0.0001),

236 irus infection that presumably resulted from blood product transfusions administered before the intro

237 Sedation, blood product transfusions as indicated, antibiotics, an

238 seropositive, and who received more than 20 blood product transfusions before BMT.

239 ostatic reoperation and the requirements for blood product transfusions during and after off-pump cor

240 to treat, 22.6), but had no effect on other blood product transfusions or major complications.

241 ocol, all subjects in the SOC group received blood product transfusions versus 5 in the TEG group (10

242 No significant clinical bleeding events or blood product transfusions were observed in this trial.

243 rs such as total parenteral nutrition (TPN), blood product transfusions, invasive procedures, central

244 ed growth factor support, and three required blood product transfusions.

245 , continuous veno-venous hemofiltration, and blood product transfusions.

246 nt has reduced intraoperative blood loss and blood product transfusions.

247 iated with major blood loss and the need for blood product transfusions.

248 ause of Jehovah's Witnesses' (JW) refusal of blood products, treatment challenges arise.

249 loid infusion volume and number of the total blood product units given in the first 24 hours decrease

250 r patient morphometry, crystalloid, colloid, blood products, urine, blood loss, duration, and approac

251 A posthoc analysis of blood product usage was performed in data obtained from

252 strates improved mortality and lower overall blood product usage with higher ratios of plasma and pla

253 associated with a short anhepatic phase, low blood product usage, and short intensive care unit stay.

254 egard to duration of surgery, intraoperative blood product usage, liver and renal function, volume of

255 (mean 6.0+/-0.17 vs. 6.3+/-0.25 hr, P=1.00), blood product usage, or any other outcome variable.

256 ch is associated with a reduction in overall blood product use and a 60% decreased odds in 30-day mor

257 Endpoints were blood product use and bleeding complications.

258 inued use of aprotinin, but rather increased blood product use has occurred with the attendant costs

259 mographic variables, diagnosis category, and blood product use history (in patients with blood group

260 However, daily blood product use is difficult to anticipate.

261 els that triggered a transfusion and overall blood product use were obtained for patients undergoing

262 , surgeon, warm and cold ischemic times, and blood product use were recorded.

263 Demographics, blood product use, primary diagnosis, cold ischemic time

264 The incidences of blood-product use, infection, and serious adverse events

265 ment of hemorrhage, including transfusion of blood products, use of hemostatic bandages/agents, and t

266 rts to support order auditing, assessment of blood product utilization and compliance monitoring.

267 that early postoperative adverse events and blood product utilization would affected in this post-ap

268 r-associated bloodstream infections, reduces blood product utilization, and improves communication du

269 ith dosage modification, or growth factor or blood product utilization.

270 A restrictive transfusion strategy halved blood product utilization.

271 enomes in living cells, the sterilization of blood products, vaccine development, and viral inactivat

272 illary outcomes included time to hemostasis, blood product volumes transfused, complications, inciden

273 In the past, transfusion of blood and blood products was an important source of HCV transmissi

274 ients tested, a history of prior exposure to blood products was associated with an increased risk of

275 ion models confirmed that the transfusion of blood products was independently associated with altered

276 The use of therapeutic blood products was significantly associated with the pre

277 fected by the increasing use of leukoreduced blood products, we followed a prospective cohort of 807

278 , when only CMV-seronegative and/or filtered blood products were provided, and period 2 (12/96-2/00),

279 Blood products were transfused in 72 (64%) patients with

280 ations were performed and 117 total units of blood products were transfused.

281 17 patients needed surgery and 264 units of blood products were used in the first 15 h, close to the

282 No blood products were used in transfusion-free patients wh

283 nown in several insects to contribute to the blood products which are endocytosed along with vitellog

284 ne priming step followed by transfusion of a blood product with either leukocyte allo-antibodies or b

285 ated 26 patients with religious objection to blood products with autologous stem-cell support without

286 ly represent venous engorgement and/or acute blood products within the spinal cord.